Table 2.
Summary of mutation and expression findings in LCMC II
| Any Genotyping (n*) | % (based on n for each assay) | CI | Full Genotyping (n=423) | % | CI | Targeted Therapy | |
|---|---|---|---|---|---|---|---|
| Major Targetable Alterations | |||||||
| EGFR | |||||||
| sEGFR | 116 (862) | 13.5% | 11-16 | 65 | 16.7% | 12-19 | 100 |
| L858R | 50 | 31 | |||||
| Exon 19 in/del | 56 | 30 | |||||
| G719X or L861Q | 10 | 4 | |||||
| MET amplification | 33 (689) | 4.8% | 3-7 | 19 | 4.9% | 3-7 | 6 |
| ALK rearrangement | 36 (843) | 4.3% | 3-6 | 17 | 4.4% | 2-6 | 30 |
| BRAF V600E | 26 (860) | 3.0% | 2-4 | 17 | 4.4% | 2-6 | 10 |
| ROS1 rearrangement | 18 (832) | 2.2% | 1.3-3 | 11 | 2.8% | 1.3-5 | 8 |
| RET rearrangement | 18 (817) | 2.2% | 1.3-4 | 11 | 2.8% | 1.3-5 | 9 |
| ERBB2 | 16 (647) | 2.5% | 1.4-4 | 12 | 3.1% | 1.5-5 | 6 |
| Other Alterations | |||||||
| KRAS | 269 (862) | 31.2% | 28-34 | 113 | 29.0% | 23-31 | 2 |
| oEGFR | 20 (861) | 2.3% | 1.4-4 | 11 | 2.8% | 1.3-5 | 0 |
| NRAS | 6 (860) | 0.7% | 0.3-2 | 5 | 1.3% | 0.4-3 | 0 |
| BRAF (non-V600E) | 8 (860) | 0.9% | 0.4-2 | 2 | 0.5% | 0.1-2 | 0 |
| AKT1 | 0 (708) | 0.0% | 0 | ||||
| Known Co-Occuring Alterations | |||||||
| MET expression (IHC) | 482 (827) | 58.3% | 55-62 | 235 | 60.3% | 51-60 | |
| TP53 mutation | 218 (431)** | 50.5% | 46-56 | 136 (274)** | 49.6% | 44-56 | |
| PTEN loss (IHC) | 54 (646) | 8.3% | 6-11 | 40 | 10.3% | 10-18 | |
| PIK3CA | 23 (860) | 2.7% | 2-4 | 15 | 3.8% | 2-6 | |
| MAP2K1 | 2 (765) | 0.3% | 0-1 | 0 |
*
n denotes the number of subjects whose cancers were tested for each alteration;
**
for TP53 mutation detection rate, only cases in which NGS testing was performed are considered